Status:
UNKNOWN
Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Tuberculosis
Psoriasis
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from p...
Detailed Description
Patients with psoriasis and psoriatic arthritis are candidates to receive anti-TNF alpha therapies which require prior screening for latent tuberculosis (LTB). Currently, screening for LTB is based on...
Eligibility Criteria
Inclusion
- Patients with psoriasis and psoriatic arthritis
- Aged 18-90
Exclusion
- History of TB
- Known allergy to TST
- Current or past treatment with anti-TNF alpha
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01223976
Start Date
November 1 2010
End Date
August 1 2011
Last Update
October 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Medical Center
Tel Aviv, Israel, 64239